Chronic Hepatitis B
Conditions
Keywords
HBV, HBV Mutation, HBV Integration, HBV Resistance
Brief summary
Patients with a confirmed diagnosis of chronic hepatitis B (CHB) who have complete clinical data and retained blood or liver tissue samples will be enrolled. All patients will be grouped based on cohort sources: the Antiviral Treatment Cohort and the Cross-Sectional Epidemiological Survey Cohort. Patients in the Antiviral Treatment Cohort have received antiviral treatment and are followed every six months. During follow-up, HBV-related endpoint events, including cirrhosis decompensations (such as ascites, esophageal variceal bleeding, and hepatic encephalopathy), hepatocellular carcinoma (HCC), liver transplantation, and liver-related death, will be collected. In the Cross-Sectional Epidemiological Survey Cohort, clinical data will be collected at a single time point, with some patients not receiving antiviral treatment. In both cohorts, retained blood and liver tissue samples will be used to further analyze HBV genotypes, viral integration, drug resistance, and the molecular characteristics of mutations. Finally, a detailed description will be provided regarding the correlation between these HBV genetic molecular features and demographic distribution, clinical phases, and various clinical outcome events.
Detailed description
To identify HBV genotypes, viral integration, drug resistance, and molecular characteristics of mutations associated with clinical immune phases and different clinical outcome events based on a representative hepatitis B clinical cohort.
Interventions
None listed
Sponsors
Beijing Friendship Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with hepatitis B surface antigen positive. * Patients who have complete demographic information, clinical data and retained blood samples or liver tissue samples
Exclusion criteria
* Subject who without blood samples or liver tissue samples
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in hepatitis B virus integration sites and count under antiviral treatment | Testing of previously collected samples within the time frame of 2015 to 2023 |
Secondary
| Measure | Time frame |
|---|---|
| Hepatitis B virus variants related to drug resistance under antiviral treatment | Testing of previously collected samples within the time frame of 2015 to 2023 |
| Genetic mutations in Hepatitis B virus across different regions and populations. | Testing of previously collected samples within the time frame of 2014 to 2023 |
| Genetic mutations in Hepatitis B virus related to different stages of disease progression | Testing of previously collected samples within the time frame of 2015 to 2023 |
Countries
China
Contacts
Primary ContactXiaoning Wu
Outcome results
None listed